Loading...

Procaps Group, S.A.

PROCWNASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$0.02
$0.005(33.79%)

Procaps Group, S.A. (PROCW) Stock Overview

Explore Procaps Group, S.A.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 63.9/100

Key Financials

Market Cap2M
P/E Ratio0.05
EPS (TTM)N/A
ROE-2.22%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$0.01

PROCW Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Procaps Group, S.A. (PROCW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 0.00, suggesting the stock is in an oversold condition. Our forecasting models predict significant price movements, with a 12-month target of $0.01.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 0.05 and a market capitalization of 2M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Frequently Asked Questions

;